Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Relmada Therapeutics (Nasdaq: RLMD) will participate in the Jefferies Global Healthcare Conference in New York from June 2-4, 2026.

Rhea-AI Summary

Relmada Therapeutics (Nasdaq: RLMD) will participate in the Jefferies Global Healthcare Conference in New York from June 2-4, 2026. CEO Sergio Traversa and CFO Maged Shenouda will join a fireside chat on Thursday, June 4, 2026, at 12:50 PM ET.

A live webcast and 90-day replay will be available via the Relmada investor relations website, and management will hold one-on-one investor meetings scheduled through Jefferies.

Argus May 28 session

-0.14% close to close Open Argus

Details

News Market Reaction – RLMD

On May 28, the day this news came out, RLMD closed 0.14% below the previous close.

Data tracked by StockTitan Argus for the May 28 session.

Market Context

This announcement highlights Relmada’s participation in the Jefferies Global Healthcare Conference, ...

Analysis

This announcement highlights Relmada’s participation in the Jefferies Global Healthcare Conference, including a fireside chat on June 4, 2026 and one-on-one investor meetings. It extends a pattern of active investor outreach following recent NDV‑01 data, PIPE financing, and strengthened cash balances detailed in SEC filings. Investors may focus on any incremental color management provides around the Phase 3 RESCUE program, sepranolone plans, and capital deployment priorities during these interactions.

Key Figures

Conference dates: June 2–4, 2026 Fireside chat date: June 4, 2026 Session time: 12:50 PM ET +1 more

Conference dates

June 2–4, 2026

Jefferies Global Healthcare Conference schedule

Fireside chat date

June 4, 2026

Relmada session date at Jefferies conference

Session time

12:50 PM ET

Scheduled time for Relmada fireside chat

Replay availability

90 days

Archived webcast available after the event

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Earnings and update

   24h Move

   +0.5%

   Q1 2026 results, strong NDV‑01 data, funding runway projected through 2029.

2. May 06

   Earnings date set

   24h Move

   +6.9%

   Announcement of timing for Q1 2026 results call and webcast.

3. May 05

   Conference abstracts

   24h Move

   -0.8%

   Plan to present NDV‑01 Phase 2 update and Phase 3 overview at AUA2026.

4. Mar 19

   Earnings and financing

   24h Move

   -2.9%

   Strong NDV‑01 data plus completion of $160M PIPE financing.

5. Mar 12

   Earnings date set

   24h Move

   -2.7%

   Scheduling of Q4 2025 results call and webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.

Jefferies Global Healthcare Conference Details
Format: Fireside Chat
Date: Thursday, June 4, 2026
Time: 12:50 PM ET
Webcast: Click Here

Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.

The webcast can also be accessed on the Events page of the Investors section of the Relmada website at https://www.relmada.com/for-investors/ir-calendar. An archived replay will be available for 90 days following the conclusion of the event.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Relmada Therapeutics (RLMD) present at the Jefferies Global Healthcare Conference 2026?

Relmada will participate in a fireside chat on Thursday, June 4, 2026, at 12:50 PM ET. According to Relmada, this session is part of the Jefferies Global Healthcare Conference in New York, held from June 2-4, 2026.

How can investors watch Relmada Therapeutics’ Jefferies Global Healthcare Conference 2026 webcast?

Investors can access a live webcast of Relmada’s fireside chat via the company’s Investors – Events webpage. According to Relmada, an archived replay of the Jefferies Global Healthcare Conference presentation will remain available online for 90 days after the event.

Will Relmada Therapeutics (RLMD) management hold one-on-one meetings at Jefferies Global Healthcare Conference 2026?

Yes, Relmada management will be available for one-on-one investor meetings during the Jefferies conference. According to Relmada, investors interested in scheduling meetings should contact their Jefferies representative to arrange a specific time during the June 2-4, 2026 event.

Who from Relmada Therapeutics will speak at the Jefferies Global Healthcare Conference 2026?

Relmada’s CEO Sergio Traversa and CFO Maged Shenouda will participate in the fireside chat session. According to Relmada, their appearance at the Jefferies Global Healthcare Conference offers investors an opportunity to hear leadership discuss the company’s strategy and clinical-stage pipeline.